Test Code: 30148
Cpt Code:83006 (x1)
For the quantitative measurement of ST2. ST2 is member of the Toll-interleukin 1 receptor family, and functions as a down-regulator of the pro-inflammatory cytokines IL-1, IL-6 and TNF-α. ST2 has been shown to be elevated in inflammatory conditions.
The assay for quantification of ST2 is a sandwich ELISA performed in a microtiter plate format. Conversion of a chromogenic substrate produces a color, the intensity of which is proportional to the concentration of ST2 in the sample material. A standard curve is used to calculate the concentration of ST2 in each of the test samples. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
Specific to human ST2.
The result is reported in ng/mL. The assay range is approximately 1.6 to 50.0 ng/mL. The reference range for a healthy population is less than 30.0 ng/mL. However it should be noted that these ranges are obtained from a limited population of apparently healthy adults and are not diagnostic thresholds.
Causes For Rejection
Invalid specimen type, inadequate volume, gross hemolysis or gross lipemia, sample not frozen upon receipt.
Test performed M, W, F. TAT 3 - 5 days from receipt of specimen.
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Viracor-IBT test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Viracor-IBT Laboratories, 1001 NW Technology Dr, Lee's Summit, MO 64086.
NY approved. Whole blood should be collected in sodium heparin tubes and plasma separated by centrifugation within 30 minutes of the draw time. 1 mL of plasma sample should be removed to a sterile tube and frozen immediately (-70°C).
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor-IBT's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor-IBT assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
Vander Lugt MT, Braun TM, Ferrara JLM, et al. Plasma Concentration of Suppressor of Tumorigenicity 2 (ST2), the IL33 Receptor, at lnitiation of Graft Versus Host Disease Therapy Predicts Day 28 Response and Day 180 Survival Post-Treatment. Biol Blood Marrow Transpl. 2012 February; 18 (2):S201-S202.
Vander Lugt MT, Braun TM, Ferrara JLM, et al. Plasma Concentration of ST2, the IL33 Receptor, AIInitiation of Graft Versus Host Disease Therapy Predicts Day 28 Response and Day 180 Survival Post-Treatment. Blood. 2011 118(21).